THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Overview Fund Activity
Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

63 hedge funds and large institutions have $95.5M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
63
Holders Change
-6
Holders Change %
-8.7%
% of All Funds
1%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
10
Increased
19
Reduced
21
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Millennium Management
Millennium Management
New York
$4.62M
2
FCMV
Foresite Capital Management V
California
$11.1M
3
O
OrbiMed
New York
$47.6M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
$696K
5
AAA
Affinity Asset Advisors
New York
$1.08M

Top Sellers

1
PBA
Paradigm Biocapital Advisors
New York
$0
2
DM
Deerfield Management
New York
$0
3
VA
VR Adviser
New York
$0
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
$0
5
Citadel Advisors
Citadel Advisors
Florida
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
MIM
76
MetLife Investment Management
New Jersey
– -$96.4K -10,330 Closed
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
– -$10.5K -1,126 Closed
Federated Hermes
78
Federated Hermes
Pennsylvania
– -$1.52K -163 Closed
1 2 3
4